Literature DB >> 2363300

Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines.

P J Watt1, B S Robinson, C R Pringle, D A Tyrrell.   

Abstract

The virulence and immunogenicity of a wild-type respiratory syncytial (RS) virus together with four temperature sensitive (ts) mutants derived from this isolate were tested by intranasal inoculation into adult volunteers. Resistance to challenge correlated with neutralizing antibody titres in nasal secretions and to a lesser extent in serum. All ts mutants were reduced in virulence. Mutant ts1B caused mild or asymptomatic infections yet induced antibody responses comparable with wild-type RS virus. Ts1B might be developed further to produce a live-virus vaccine.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2363300     DOI： 10.1016/0264-410x(90)90051-m

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  19 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

Review 2.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

3.  Analysis of respiratory syncytial virus strain variation in successive epidemics in one city.

Authors:  P A Cane; D A Matthews; C R Pringle
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

Review 4.  Progress in respiratory virus vaccine development.

Authors:  Alexander C Schmidt
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

Review 5.  Respiratory syncytial virus infection in adults.

Authors:  A R Falsey; E E Walsh
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

Review 6.  Vaccines for the common cold.

Authors:  Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

7.  Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses.

Authors:  Richard Singleton; Nathalie Etchart; Sam Hou; Lisa Hyland
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

8.  Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice.

Authors:  R Weltzin; S A Hsu; E S Mittler; K Georgakopoulos; T P Monath
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

9.  Live-attenuated respiratory syncytial virus vaccines.

Authors:  Ruth A Karron; Ursula J Buchholz; Peter L Collins
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

10.  Epitope specificities of human serum antibodies reactive with respiratory syncytial virus fusion protein.

Authors:  B S Robinson; J S Everson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.